АЛКОГОЛЬНАЯ БОЛЕЗНЬ ПЕЧЕНИ. ЧАСТЬ 2
https://doi.org/10.20514/2226-6704-2013-0-1-60-63
Abstract
The article represents contemporary data on the illness development mechanisms, the main disease manifestation forms and the treatment methods of the alcoholic liver disease. It also covers the disease progression reasons and the main risk factors.
Keywords
About the Author
Е. Ю. Еремина
ФГБОУ ВПО «Мордовский государственный университет им. Н.П. Огарева»
Russian Federation
кафедра пропедевтики внутренних болезней, директор гастроэнтерологического центра, г. Саранск
Russian Federation
кафедра пропедевтики внутренних болезней, директор гастроэнтерологического центра, г. Саранск
References
1. Абдурахманов Д.Т. Алкогольный гепатит.// Клиническая гепатология. 2008. 4(2). С. 3–10.
2. Буеверов А.О., Павлов А.И., Ивашкин В.Т. Алкогольная болезнь печени: возможно ли улучшение прогноза?//Клинические перспективы гастроэнтерологии и гепатологии. 2011. № 2. С 3–10.
3. Майер К.П. Гепатиты и последствия гепатита. М.: Гэотар, 2004. с. 720.
4. Abittan C., Lieber C. Alcoholic liver disease. Clin. Perspect. in Gastroenterol. 1999; Sept.Oct.: 25763.
5. Achord J.L. Review and treatment of alcoholic hepatitis: a metaanalysis adjusting for confounding variables. Gut 1995; 37: 1138.
6. Akriviadis E., Bolta R., Briggs W. Pentoxifylline improves short–term survival in severe acute alcoholic hepatitis: A double–blind, placebo–controlled trial. Gastroenterology, 2000, 119, 1637.
7. Angelico M., Gandin C. Recombinant interferon-alpha and UDCA versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up Am. J.Gastroenterology 1995; 90: 263–269.
8. Bosron W.F., Ehrig T., Li T.K. Genetic factors in alcohol metabolism and alcoholism. Sem Liver Dis 1993; 13: 26–38.
9. Chen W., Liu Y., Glund C. Bile acids for viral hepatitis, 2003. Cochrane Database Syst Rev 2003; 2: CD 003181.
10. Fabbri C., Marchetto S., Pezzoli A. et al. Efficacy of UDCA in association with alpha- interferon for chronic hepatitis C in alpha- interferon nonresponder patients. Eur. J. of Gastroenterol. Hepatol. 2000; 12 (5): 511–515.
11. Kono H., Rusyn I., Yin M. NADPH oxidase–derived free radicals are key oxidants in alcohol–induced liver disease. J Clin Invest, 2000; 106:867.
12. Mioni D., Burra P., Pujatti A. et al. Carbohydrate deficient transferrin levels in alcohol abusers with and without severe liver disease. Gut 1997; 43(1):181.
13. O’Shea R.S., Dasarathy S., McCullough A.J. Alcoholic liver disease. Hepatology, 2010, 51, 307–328.
14. Plevris J.N., Hayes P.C., Bouchier I.A.D. Ursodeoxycholic acid in the treatment of alcoholic liver disease. Eur J Gastroenterol Hepatol 1991; 3: 65–36.
15. Rolla R., Vay D., Mottaran E. Detection of circulating antibodies against malondialdehyde–acetaldehyde adducts in patients with alcohol–induced liver disease. Hepatology, 2000; 31: 878.
16. Wheeler M. Ethanol and HCV–induced cytotoxicity: the perfect storm. Gastroenterology, 2005, 128, 232–4.
Review
For citations:
Еремина Е.Ю. АЛКОГОЛЬНАЯ БОЛЕЗНЬ ПЕЧЕНИ. ЧАСТЬ 2. The Russian Archives of Internal Medicine. 2013;(1):60-63. (In Russ.) https://doi.org/10.20514/2226-6704-2013-0-1-60-63
Views:
917
Email this article 